1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world patterns of care among patients with metastatic pancreatic cancer (mPC)
    Meeting Abstract

    O'Reilly, E. M.; Surinach, A.; Wu, Z.; Cockrum, P.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P)
    Meeting Abstract

    Macarulla, T.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions
    Meeting Abstract

    Makawita, S.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ly, M.; Molena, D.; Sihag, S.; Wu, A. J. C.; Shah, P. M.; Gu, P.; Sugarman, R.; Maron, S. B.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Abou-Alfa, G. K.; Shi, Y.; Whang-Peng, J.; Yuen, M. F.; Saif, W. M.; Tian, A.; Gu, S.; Lam, W.; Liu, S. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
    Meeting Abstract

    Javle, M. M.; Shaib, W. L.; Braun, S.; Engelhardt, M.; Borad, M. J.; Abou-Alfa, G. K.; Boncompagni, A.; Friedmann, S.; Gahlemann, C. G.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H. S.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Hong, Y. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Meeting Abstract

    Hall, M. J.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save